Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 16, 2022; 10(14): 4669-4675
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4669
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4669
PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
Hong-Qiang Zhang, Chang-Zhi Huang, Jing-Yu Wu, Zhen-Ling Wang, Yu Shao, Zan Fu, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Author contributions: Zhang HQ designed the writing ideas and wrote the manuscript; Huang CZ participated in the operation of the patient as an assistant and made important modifications to the manuscript; Wu JY, Wang ZL, and Shao Y collected patient's data and followed the patient; Fu Z performed the surgery and developed the patient's treatment plan; all authors have read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zan Fu, MD, Chief Doctor, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. fuzan1971@njmu.edu.cn
Received: January 9, 2022
Peer-review started: January 9, 2022
First decision: February 21, 2022
Revised: March 3, 2022
Accepted: March 27, 2022
Article in press: March 27, 2022
Published online: May 16, 2022
Peer-review started: January 9, 2022
First decision: February 21, 2022
Revised: March 3, 2022
Accepted: March 27, 2022
Article in press: March 27, 2022
Published online: May 16, 2022
Core Tip
Core Tip: A 30-year-old man was diagnosed with microsatellite unstable colon cancer. Prior to his surgical treatment, he was treated with a neoadjuvant regimen of PD1 inhibitors in combination with fruquintinib. This neoadjuvant regimen is rarely used; however, this patient had a good outcome. Subsequently, we performed a laparoscopic radical resection of his right colon cancer, which revealed no microscopic tumour cells. The patient was in good condition after the surgical treatment.